Herantis Pharmas clinical study with CDNF in Parkinsons disease authorized in Sweden
Herantis Pharma's clinical study with CDNF in Parkinson's disease authorized in Sweden Herantis Pharma PlcCompany release 23 March 2017 at 12:30 pm The Medicines Agency of Sweden, MPA, has authorized Herantis Pharma Plc's ("Herantis") first-in-human clinical study of the company's investigational product CDNF for the treatment of Parkinson's disease. Patient recruitment in the randomized, placebo-controlled Phase 1-2 clinical study is planned to begin in Sweden in the first half of 2017. "CDNF is a novel neurotrophic and neuroprotective factor, which affects several mechanisms